

This Document can be made available in alternative formats upon request

State of Minnesota

Printed Page No.

133

HOUSE OF REPRESENTATIVES

NINETIETH SESSION

H. F. No. 1832

- 03/01/2017 Authored by Kiel
- The bill was read for the first time and referred to the Committee on Commerce and Regulatory Reform
- 03/15/2017 Adoption of Report: Placed on the General Register
- Read for the Second Time
- 05/01/2017 Referred to the Chief Clerk for Comparison with S. F. No. 1627
- 05/04/2017 Postponed Indefinitely

1.1 A bill for an act

1.2 relating to health; requiring health plans to indicate level of coverage for certain

1.3 anticancer medication; amending Minnesota Statutes 2016, section 62A.3075.

1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 Section 1. Minnesota Statutes 2016, section 62A.3075, is amended to read:

1.6 **62A.3075 CANCER CHEMOTHERAPY TREATMENT COVERAGE.**

1.7 (a) A health plan company that provides coverage under a health plan for cancer

1.8 chemotherapy treatment shall not require a higher co-payment, deductible, or coinsurance

1.9 amount for a prescribed, orally administered anticancer medication that is used to kill or

1.10 slow the growth of cancerous cells than what the health plan requires for an intravenously

1.11 administered or injected cancer medication that is provided, regardless of formulation or

1.12 benefit category determination by the health plan company.

1.13 (b) A health plan company must not achieve compliance with this section by imposing

1.14 an increase in co-payment, deductible, or coinsurance amount for an intravenously

1.15 administered or injected cancer chemotherapy agent covered under the health plan.

1.16 (c) Nothing in this section shall be interpreted to prohibit a health plan company from

1.17 requiring prior authorization or imposing other appropriate utilization controls in approving

1.18 coverage for any chemotherapy.

1.19 (d) A plan offered by the commissioner of management and budget under section 43A.23

1.20 is deemed to be at parity and in compliance with this section.

1.21 (e) A health plan company is in compliance with this section if it does not include orally

1.22 administered anticancer medication in the fourth tier of its pharmacy benefit.

2.1 (f) A health plan company that provides coverage under a health plan for cancer
2.2 chemotherapy treatment must indicate the level of coverage for orally administered anticancer
2.3 medication within its pharmacy benefit filing with the commissioner.

2.4 **EFFECTIVE DATE.** This section is effective January 1, 2018, and applies to health
2.5 plans offered, sold, issued, or renewed on or after that date.